CM
XLRN

Castleark Management’s Acceleron Pharma XLRN Stock Holding History

Castleark Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,635
Closed -$251K – 385
2020
Q2 		$251K Buy
+2,635
New +$254K 0.01% 294

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Castleark Management's XLRN Position: Q3 2020 in Review

Castleark Management sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 2,635 shares — an estimated $251K sold.

Castleark Management first reported a position in XLRN in Q2 2020 and held it in 1 quarter. The position peaked at $251K in Q2 2020. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

  • Castleark Management reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
  • Castleark Management sold 2,635 Acceleron Pharma shares in Q3 2020, an estimated $251K.
  • Castleark Management first reported a position in Acceleron Pharma in Q2 2020 and held it in 1 quarter.
  • Castleark Management's Acceleron Pharma position peaked at $251K in Q2 2020.
  • 238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Castleark Management's 13F filing for Q3 2020, filed 16 Nov 2020.